FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths [Yahoo! Finance]
Kezar Life Sciences, Inc. (KZR)
Last kezar life sciences, inc. earnings: 8/7 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
via teleconference with the FDA that the zetomipzomib Investigational New Drug (IND) application for lupus nephritis (LN) has been placed on clinical hold Lupus nephritis is a type of kidney disease caused by systemic lupus erythematosus link (SLE or lupus). Lupus is an autoimmune disease link—a disorder in which the body's immune system attacks the body's cells and organs. The action follows Kezar's communication to the FDA that Kezar was voluntarily suspending enrollment and dosing in its Phase 2b PALIZADE trial of zetomipzomib in lupus nephritis patients at the recommendation of the trial's Independent Data Monitoring Committee (IDMC). The IDMC's recommendation followed their review of emerging safety data, including an assessment of four Grade 5 (fatal or death) serious adverse events (SAEs) that occurred during the trial in patients enrolled in the Philippines and Argentina. The FDA indicated they will provide Kezar with an official clinical hold letter within 30 days.
Show less
Read more
Impact Snapshot
Event Time:
KZR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZR alerts
High impacting Kezar Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
KZR
News
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $9.00. They now have an "equal weight" rating on the stock.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.MarketBeat
- Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.MarketBeat
- Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
KZR
Earnings
- 11/12/24 - Beat
KZR
Sec Filings
- 12/3/24 - Form 8-K
- 11/14/24 - Form 8-K
- 11/14/24 - Form SCHEDULE
- KZR's page on the SEC website